Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

14

Revenue 2017

Opdivo

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Opdivo was produced by Gilead Sciences.

Modest meeting sees only two drugs recommended by CHMP

Modest meeting sees only two drugs recommended by CHMP The CHMP also noted the withdrawal of Bristol-Myers Squibb’s Opdivo (nivolumab) and Yervoy (iplimumab) application, which was seeking marketing authorisation in first-line metastatic non-small cell lung cancer.

BMS scores first oesophageal cancer nod for Opdivo in Japan

BMS scores first oesophageal cancer nod for Opdivo in Japan Opdivo met the primary endpoint of overall survival (OS), demonstrating a 23% reduction in the risk of death and a 2.5 month improvement in OS when compared to chemotherapy. ... The survival benefit with Opdivo treatment was observed regardless of tumour

BMS’ Opdivo combo misses the mark in pancreatic cancer

BMS’ Opdivo combo misses the mark in pancreatic cancer Patients were randomised to receive the Opdivo/cabiralizumab combination, chemotherapy alone, or the Opdivo/cabiralizumab with one of two different chemotherapy regimens. ... The blow is more significant for Five Prime than it is for BMS – the

FDA sets June decision date for Tecentriq monotherapy in NSCLC

FDA sets June decision date for Tecentriq monotherapy in NSCLC Bristol-Myers Squibb’s own PD-1 inhibitor Opdivo(nivolumab) is currently under review with the FDA, in combination with low-dose CTLA4 inhibitor Yervoy (ipilimumab) in previously-untreated NSCLC patients

BMS unveils long-term results for Opdivo in kidney cancer

BMS unveils long-term results for Opdivo in kidney cancer Results include updated data for Opdivo with or without Yervoy. Bristol-Myers Squibb has unveiled long-term results for Opdivo in renal cell carcinoma, which demonstrated efficacy with and without CTLA4 ... BMS also reported updated results from its

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Envision Pharma Group

We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...

Latest intelligence

Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...
A snapshot of… Exscientia
...
Patients are ready for virtual clinical trials, are you?
Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...

Infographics